TGA Response: Prohibited Ingredients in E-Cigarettes

Regulations by 2FIRSTS.ai
Jun.21.2023
TGA Response: Prohibited Ingredients in E-Cigarettes
Australian authority fines and issues infringement notices to e-cigarette importers for containing banned ingredients.

The Therapeutic Goods Administration (TGA) in Australia had issued 38 infringement notices and imposed fines totalling AUD 588,840 against four importers of e-cigarettes for violating regulations.

 

The TGA laboratory has found prohibited substances in disposable e-cigarette samples from the brands IGET, GUNNPOD, and HQD, as per the therapeutic goods order for nicotine e-cigarette products (TGO 110) for 2021.

 

In response to the incident, 2FIRSTS promptly conducted an email interview with TGA. On June 21st, TGA Spokesperson replied to 2FIRSTS via email. TGA stated in their response that the disposable e-cigarette products IGET Bar, IGET Legend, GUNNPOD, and HQD were found to contain three prohibited ingredients: benzaldehyde, cinnamaldehyde, and ethylene glycol. According to a search on the TGA official website, (Standard for Nicotine Vaping Products) (TGO 110) Order 2021 specifies the three ingredients are prohibited in e-cigarette products.

 

The following response is from a spokesperson for the Australian Therapeutic Goods Administration.

 

Please attribute the following response to a spokesperson the Therapeutic Goods Administration.

 

1.Is it possible to announce the prohibited ingredients contained in IGET, GUNPOD and HQD branded vapes referenced in the media release?

 

Testing conducted by Therapeutic Goods Administration (TGA) Laboratories identified the IGET Bar and IGET Legend disposable pod devices contained benzaldehyde, cinnamaldehyde and ethylene glycol; Gunnpod disposable pod devices were found to contain benzaldehyde and ethylene glycol; and HQD disposable pod devices were found to contain benzaldehyde, cinnamaldehyde and ethylene glycol.

 

2.Will there be other punishments for the enterprises named, such as arrests? Will the enterprises that produce and manufacture these products also be punished?

 

Infringement notices are one of the compliance tools the TGA can use when we believe that a requirement of the Therapeutic Goods Act 1989 has been breached. If an entity does not pay the infringement notice, the TGA may take further action such as formal court action.

 

The Therapeutic Goods Act 1989 regulates the import, export, supply, manufacture and supply of therapeutic goods within Australia. As the products subject to the infringement notices are manufactured outside of Australia, the manufacturers are not subject to Australian laws.

 

3.Will TGA strengthen supervision in the future?

 

On 2 May 2023, the Minister for Health and Aged Care announced that the Australian Government is taking strong action to combat the supply of unlawful vaping products. The TGA is working closely with state and territory governments and the Australian Border Force to introduce a comprehensive range of reforms, including:

  • stopping the import of non-prescription vapes;
  • increasing the minimum quality standards for vapes including by restricting flavours, colours, and other ingredients;
  • requiring pharmaceutical-like packaging;
  • reducing nicotine concentrations and volumes;
  • banning all single use disposable vapes; and
  • ending vape sales in convenience stores and other retail settings.

 

Note: The previously mentioned "GUNPOD" should be corrected to "GUNNPOD," as stated by TGA in their email reply.

 

Reference(s):

 

Three TSG stores based in Sydney and Jaradat and Sabbagh Group Pty Ltd have been issued with infringement notices totalling $588,840.

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
Feb.11
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
As the FDA advances efforts to streamline its PMTA review process, including support for small businesses, expectations are rising that additional product authorizations may follow. Age-verification technology is emerging as a key consideration in future approvals.In this interview, California-based Glas discusses its G2 platform, integrating smartphone-based identity verification, proximity controls and anti-counterfeit systems, and outlines its positioning under the FDA’s PMTA framework.
Mar.02
2Firsts|Sesh Advances Nicotine Pouch PMTA to Filing Stage, Experts Highlight Regulatory Threshold and Market Window
2Firsts|Sesh Advances Nicotine Pouch PMTA to Filing Stage, Experts Highlight Regulatory Threshold and Market Window
Sesh said its Premarket Tobacco Product Application (PMTA) for 64 nicotine pouch SKUs has been accepted by the U.S. Food and Drug Administration (FDA) and advanced to the Filing stage, entering substantive scientific review. Industry experts say the development signals that the application has crossed a key technical and regulatory threshold, while also highlighting growing divergence in regulatory capability and market positioning within the nicotine pouch category.
Special Report
Mar.24 by 2FIRSTS.ai
STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
Scandinavian Tobacco Group UK (STG UK) has announced a rebrand across its XQS nicotine pouch range. The updated packaging will be visible at retail from March, with the recommended retail price remaining £5.50. The new packs feature a bolder logo and glossy textures, retain nicotine strength indicators, and add a side flavour profile indicator to show the flavour type.
Feb.28 by 2FIRSTS.ai
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
Philip Morris International (PMI) released its Q4 and full-year 2025 results on February 6, 2026. PMI reported full-year net revenues of $40,648 million ($40.6 billion), reported diluted EPS of $7.26 and adjusted diluted EPS of $7.54. PMI said smoke-free net revenues were $16.9 billion and represented 41.5% of total net revenues, with smoke-free products available in 106 markets and over 43 million estimated adult consumers.
Feb.06 by 2FIRSTS.ai